We found the ratio of p-mTOR to mTOR was higher in ccRCC than adjacent tissues, p-mTOR was identified as a poor prognostic factor of CSS, and mTOR was associated with numerous immune features in ccRCC patients, which validated mTOR could be implicated in the initiation and progression of ccRCC. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.